Chronic Intranasal Treatment with an Anti-Aβ30-42 scFv Antibody Ameliorates Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease

Cattepoel, S., et al., 6(4), e18296, PLoS ONE, 2011

The authors characterized a scFv generated by grafting the complementarity determining regions (CDRs) of the VH and VL domains of the 22C4 IgG into a human scFv framework. The resulting 22C4 scFv was expressed in E. coli and characterized in terms of its binding characteristics, and its potential to inhibit Ab aggregation and prevent Ab-induced neurotoxicity. Affinity (KD) values for 22C4 scFv and 22C4 IgG binding to A-beta(1-42) were determined using the Octet platform. For these studies, biotinylated A-beta(1-42) was immobilized on Streptavidin biosensors.

Read More